<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03543657</url>
  </required_header>
  <id_info>
    <org_study_id>19352</org_study_id>
    <nct_id>NCT03543657</nct_id>
  </id_info>
  <brief_title>Maintenance Treatment of Renal Anemia in Dialysis Subjects</brief_title>
  <acronym>MIYABI HD-M</acronym>
  <official_title>A Randomized, Active-controlled, Double-blinded, Double-dummy, Parallel-group, Multicenter Study to Investigate the Efficacy and Safety of Oral Molidustat in Comparison to Darbepoetin Alfa in Dialysis Subjects Treated With Erythropoiesis-Stimulating Agents (ESAs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of molidustat in comparison
      to darbepoetin alfa in dialysis subjects with renal anemia who are treated with
      Erythropoiesis-Stimulating Agents (ESAs).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 23, 2018</start_date>
  <completion_date type="Actual">December 24, 2019</completion_date>
  <primary_completion_date type="Actual">August 7, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The mean Hb level during the evaluation period</measure>
    <time_frame>From week 33 to 36</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in mean Hb level during the evaluation period from baseline</measure>
    <time_frame>Baseline and week 33 to 36</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Responder rate: proportion of responders among the subjects</measure>
    <time_frame>From week 33 to 36</time_frame>
    <description>Responder is defined as meeting all of the following criteria:
(i) Mean of the Hb levels in the target range (ii) ≥ 50% of the Hb levels in the target range (iii) No rescue treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who meet each component of the response</measure>
    <time_frame>From week 33 to 36</time_frame>
    <description>Response:
(i) Mean of the Hb levels in the target range (ii) ≥ 50% of the Hb levels in the target range (iii) No rescue treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hb level</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hb level</measure>
    <time_frame>Baseline and up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects whose mean hemoglobin level is in the target range</measure>
    <time_frame>From week 33 to 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects whose mean hemoglobin level is above the target range</measure>
    <time_frame>From week 33 to 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects whose mean hemoglobin level is below the target range</measure>
    <time_frame>From week 33 to 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with hemoglobin levels in the target range</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with hemoglobin levels above the target range</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with hemoglobin levels below the target range</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects whose maximum rise in Hb between each consecutive visits is above 0.5 g/dL/week</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Defined as change in Hb level / duration between two visits (weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with serious adverse events</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax)</measure>
    <time_frame>At baseline, week 8, week 24 and week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC)</measure>
    <time_frame>At baseline, week 8, week 24 and week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EPO (Erythropoietin) serum concentration</measure>
    <time_frame>At baseline, week 8, week 24 and week 52</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">229</enrollment>
  <condition>Anemia</condition>
  <condition>Renal Insufficiency, Chronic</condition>
  <arm_group>
    <arm_group_label>Molidustat group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in the molidustat group will receive molidustat and darbepoetin alfa placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Darbepoetin alfa group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in the darbepoetin alfa group will receive molidustat placebo and darbepoetin alfa.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Molidustat (BAY85-3934)</intervention_name>
    <description>Starting dose of molidustat will be titrated based on the subject's Hb (Hemoglobin) response. Administrated orally once daily (OD).</description>
    <arm_group_label>Molidustat group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darbepoetin alfa</intervention_name>
    <description>Starting dose of darbepoetin alfa will be titrated based on the subject's Hb (Hemoglobin) response. Administrated weekly or once every two weeks by intravenous injection.</description>
    <arm_group_label>Darbepoetin alfa group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of Molidustat (BAY85-3934)</intervention_name>
    <description>Matching placebo of Molidustat.</description>
    <arm_group_label>Darbepoetin alfa group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of Darbepoetin alfa</intervention_name>
    <description>Matching placebo of Darbepoetin alfa.</description>
    <arm_group_label>Molidustat group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject with ESKD (end-stage kidney disease) on regular dialysis (including,
             hemodiafiltration, hemofiltration, hemodialysis, and other modalities except for
             peritoneal dialysis) weekly or more than weekly for at least 12 weeks prior to
             randomization

          -  Body weight (after dialysis) &gt; 40 and ≤ 160 kg at screening

          -  Male or female subject ≥ 20 years of age at screening

          -  At least one kidney

          -  Treated with weekly or bi-weekly dose of darbepoetin alfa, monthly or bi-weekly dose
             of epoetin beta pegol, OR weekly, biweekly, twice or three times per week dose of
             epoetin alfa/beta, and having had no more than one dose change within 8 weeks prior to
             randomization

          -  Mean screening Hb level ≥ 9.5 and &lt; 12.0 g/dL (mean of all central laboratory Hb
             levels before dialysis [at least 2 measurements must be taken ≥ 2 days apart] during
             the screening period, AND all Hb level must be measured by the central laboratory, AND
             the difference between the lowest level and highest level is &lt; 1.2 g/dL), with the
             last screening Hb level measurement within 14 days prior to randomization

          -  Ferritin ≥ 100 ng/mL or transferrin saturation ≥ 20% at screening

          -  Serum folate level and serum vitamin B12 level above lower limit of normal (LLN) at
             screening

        Exclusion Criteria:

          -  New York Heart Association (NYHA) Class III or IV congestive heart failure

          -  History of cardio- (cerebro-) vascular events (e.g., unstable angina, myocardial
             infarction, stroke, pulmonary thromboembolism, and acute limb ischemia) within 6
             months prior to randomization

          -  Sustained, poorly controlled arterial hypertension (defined as systolic BP (blood
             pressure) ≥ 180mmHg or diastolic BP ≥ 110mmHg) or hypotension (defined as systolic BP
             &lt; 90mmHg) at randomization

          -  Proliferative choroidal or retinal disease, such as neovascular agerelated macular
             degeneration or proliferative diabetic retinopathy requiring invasive treatment (e.g.,
             intraocular injections or laser photocoagulation) at screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hakuyoukai Medical corporation Hakuyoukai Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>465-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinkashiwa Clinic</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-0084</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kisarazu Clinic</name>
      <address>
        <city>Kisarazu</city>
        <state>Chiba</state>
        <zip>292-0805</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kuwajima Clinic</name>
      <address>
        <city>Niihama</city>
        <state>Ehime</state>
        <zip>792-0812</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sabae kidney Clinic</name>
      <address>
        <city>Sabae</city>
        <state>Fukui</state>
        <zip>916-0044</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houshikai Kano hospital</name>
      <address>
        <city>Kasuya-gun</city>
        <state>Fukuoka</state>
        <zip>811-0120</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Yahata General Hospital</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <zip>805-0050</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanshikai Toho Hospital</name>
      <address>
        <city>Midori</city>
        <state>Gunma</state>
        <zip>379-2311</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asahikawa-Kosei General Hospital</name>
      <address>
        <city>Asahikawa</city>
        <state>Hokkaido</state>
        <zip>078-8211</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Koizumi Cardiology Medical Clinic</name>
      <address>
        <city>Chitose</city>
        <state>Hokkaido</state>
        <zip>066-0062</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ishikari Hospital</name>
      <address>
        <city>Ishikari</city>
        <state>Hokkaido</state>
        <zip>061-3213</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Itami Kidney Clinic</name>
      <address>
        <city>Noboribetsu</city>
        <state>Hokkaido</state>
        <zip>059-0026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Souen Central Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-0008</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ibaraki Prefectural Central Hospital</name>
      <address>
        <city>Kasama</city>
        <state>Ibaraki</state>
        <zip>309-1793</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Koga Hospital</name>
      <address>
        <city>Koga</city>
        <state>Ibaraki</state>
        <zip>306-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mito Kyodo General Hospital</name>
      <address>
        <city>Mito</city>
        <state>Ibaraki</state>
        <zip>310-0015</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokiwa Clinic</name>
      <address>
        <city>Totte</city>
        <state>Ibaraki</state>
        <zip>302-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tsuchiura Beryl Clinic</name>
      <address>
        <city>Tsuchiura</city>
        <state>Ibaraki</state>
        <zip>300-0062</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kikuchi Medical Clinic</name>
      <address>
        <city>Tsukuba</city>
        <state>Ibaraki</state>
        <zip>305-0861</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Public Central Hospital of Matto Ishikawa</name>
      <address>
        <city>Hakusan</city>
        <state>Ishikawa</state>
        <zip>924-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaisei Hospital</name>
      <address>
        <city>Sakaide</city>
        <state>Kagawa</state>
        <zip>762-0007</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Honatsugi Medical Clinic</name>
      <address>
        <city>Atsugi</city>
        <state>Kanagawa</state>
        <zip>243-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chigasaki Central Clinic</name>
      <address>
        <city>Chigasaki</city>
        <state>Kanagawa</state>
        <zip>253-0052</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toshiba Rinkan Hospital</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <zip>252-0385</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama Jin Clinic</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>224-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eda Clinic</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>225-0015</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaminagaya Saitou Clinic</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>233-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seisuikai Yoshioka Mahoroba Clinic</name>
      <address>
        <city>Kurokawa-gun</city>
        <state>Miyagi</state>
        <zip>981-3632</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eijinkai Hospital</name>
      <address>
        <city>Osaki</city>
        <state>Miyagi</state>
        <zip>989-6117</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iida Hospital</name>
      <address>
        <city>Iida</city>
        <state>Nagano</state>
        <zip>395-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanno Dialysis &amp; Vascular Access Clinic</name>
      <address>
        <city>Matsumoto</city>
        <state>Nagano</state>
        <zip>390-0821</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matsumoto City Hospital</name>
      <address>
        <city>Matsumoto</city>
        <state>Nagano</state>
        <zip>390-1401</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maruko Central Hospital</name>
      <address>
        <city>Ueda</city>
        <state>Nagano</state>
        <zip>386-0405</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arisawa General Hospital</name>
      <address>
        <city>Hirakata</city>
        <state>Osaka</state>
        <zip>573-1195</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toyonaka Keijinkai Clinic</name>
      <address>
        <city>Toyonaka</city>
        <state>Osaka</state>
        <zip>560-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanyu General Hospital</name>
      <address>
        <city>Hanyu</city>
        <state>Saitama</state>
        <zip>348-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Higashimatsuyamakohjin Clinic</name>
      <address>
        <city>Higashimatsuyama</city>
        <state>Saitama</state>
        <zip>355-0016</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiyu Clinic</name>
      <address>
        <city>Koshigaya</city>
        <state>Saitama</state>
        <zip>343-0823</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Todachuo General Hospital</name>
      <address>
        <city>Toda</city>
        <state>Saitama</state>
        <zip>335-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hachioji Azumacho Clinic</name>
      <address>
        <city>Hachioji</city>
        <state>Tokyo</state>
        <zip>192-0082</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kodaira Kitaguchi Clinic</name>
      <address>
        <city>Kodaira</city>
        <state>Tokyo</state>
        <zip>187-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Hill Hospital</name>
      <address>
        <city>Ube</city>
        <state>Yamaguchi</state>
        <zip>755-0155</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inage Hospital</name>
      <address>
        <city>Chiba</city>
        <zip>263-0043</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ikeda Vascular Access Nephrology Dialysis</name>
      <address>
        <city>Fukuoka</city>
        <zip>810-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oohashi internal medicine circulatory Clinic</name>
      <address>
        <city>Fukuoka</city>
        <zip>815-0038</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ueki Imafuji Clinic</name>
      <address>
        <city>Kumamoto</city>
        <zip>861-0135</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Suzukihinyoukika</name>
      <address>
        <city>Nagano</city>
        <zip>380-0904</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagasaki Kidney Hospital</name>
      <address>
        <city>Nagasaki</city>
        <zip>850-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akagaki Clinic</name>
      <address>
        <city>Osaka</city>
        <zip>543-0052</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nishi Shinryosho</name>
      <address>
        <city>Osaka</city>
        <zip>552-0007</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chibune Clinic</name>
      <address>
        <city>Osaka</city>
        <zip>555-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iwatsuki-minami Hospital</name>
      <address>
        <city>Saitama</city>
        <zip>339-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamagata Tokushukai Hospital</name>
      <address>
        <city>Yamagata</city>
        <zip>990-0834</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 22, 2018</study_first_submitted>
  <study_first_submitted_qc>May 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2018</study_first_posted>
  <last_update_submitted>February 14, 2020</last_update_submitted>
  <last_update_submitted_qc>February 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

